Opexa Therapeutics Inc. (NASDAQ:OPXA) shares traded down 4.9% during mid-day trading on Wednesday . The company traded as low as $3.13 and last traded at $3.27, with a volume of 71,142 shares changing hands. The stock had previously closed at $3.44.

A number of research analysts have issued reports on the company. Maxim Group set a $18.00 price target on Opexa Therapeutics and gave the stock a “buy” rating in a research report on Tuesday. Aegis boosted their price target on Opexa Therapeutics to $11.00 and gave the stock a “buy” rating in a research report on Monday, July 18th. Zacks Investment Research upgraded Opexa Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 3rd. Finally, Chardan Capital reiterated a “buy” rating and set a $6.00 price target on shares of Opexa Therapeutics in a research report on Sunday, August 14th.

The company has a 50 day moving average price of $4.12 and a 200-day moving average price of $3.28. The stock’s market cap is $22.56 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/opexa-therapeutics-inc-opxa-trading-down-4-9.html

Opexa Therapeutics (NASDAQ:OPXA) last issued its earnings results on Thursday, August 11th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by $0.07. Opexa Therapeutics had a negative return on equity of 109.48% and a negative net margin of 324.97%. During the same period last year, the firm earned ($0.56) earnings per share. On average, analysts forecast that Opexa Therapeutics Inc. will post ($1.12) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Opexa Therapeutics stock. Vanguard Group Inc. increased its position in Opexa Therapeutics Inc. (NASDAQ:OPXA) by 5.6% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 164,354 shares of the biopharmaceutical company’s stock after buying an additional 8,649 shares during the period. Vanguard Group Inc. owned approximately 2.35% of Opexa Therapeutics worth $679,000 at the end of the most recent quarter. Institutional investors own 6.40% of the company’s stock.

About Opexa Therapeutics

Opexa Therapeutics, Inc (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology.

5 Day Chart for NASDAQ:OPXA

Receive News & Ratings for Opexa Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.